• Policy
• Gvnt agrees on the need for dispensing substitute drugs
• by Lee, Jeong-Hwan Oct 30, 2024 05:54am

• Company
• Dupixent sales skyrocket with 'expanded indications'
• by Son, Hyung Min Oct 30, 2024 05:54am

• Product
• KMA ‘non-face-to-face Wegovy prescriptions cause harm'
• by Kang, Shin-Kook Oct 30, 2024 05:53am

• Opinion
• [Reporter's View] Super precision medicine
• by Eo, Yun-Ho Oct 30, 2024 05:53am

• Company
• "Early intervention" needed for treating multiple myeloma
• by Whang, byung-woo Oct 29, 2024 05:49am

• Company
• Will the third time be the charm for Mylotarg?
• by Eo, Yun-Ho Oct 29, 2024 05:49am

• Company
• ABL Bio receives ₩7B as milestone payment from Sanofi
• by Kim, Jin-Gu Oct 29, 2024 05:49am

• Policy
• Low reimb approval rate hinders Soliris’s use for aHUS
• by Lee, Tak-Sun Oct 29, 2024 05:49am

• Policy
• COVID-19 treatments 'Paxlovid·Veklury' reimb begins today
• by Lee, Jeong-Hwan Oct 28, 2024 05:54am

• Company
• 'Aquipta,' new oral migraine drug, can be prescribed
• by Eo, Yun-Ho Oct 28, 2024 05:53am